We are live on ! Find out more
BIAF icon

bioAffinity Technologies
BIAF

8 hedge funds and large institutions have $231K invested in bioAffinity Technologies in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more capital invested

Capital invested by funds: $140K → $231K (+$90.8K)

33% more funds holding

Funds holding: 6 → 8 (+2)

0.37% more ownership

Funds ownership: 1.27% → 1.64% (+0.37%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
8
Holders Change
+2
Holders Change %
+33.33%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$52.6K
2
IA
IFP Advisors
Florida
+$7.06K

Top Sellers

Rank Fund Capital Flow
1
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
-$5.13K
2
TRCT
Tower Research Capital (TRC)
New York
-$1.28K
3
UBS Group
UBS Group
Switzerland
-$76

BIAF Hedge Fund Activity: Q4 2023 in Review

8 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAF) for Q4 2023, worth a combined $231K — up 65% from $140K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new BIAF positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 2 trimmed.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $52.6K. The largest seller was CAPTRUST Financial Advisors, cutting an estimated $5.13K.

  • 8 institutional investors held bioAffinity Technologies (BIAF) as of Q4 2023, up from 6 in Q3 2023.
  • Funds reported $231K of bioAffinity Technologies stock for Q4 2023, up 65% quarter-over-quarter.
  • 2 funds opened new bioAffinity Technologies positions in Q4 2023 and 0 closed out, a net change of +2 holders.
  • The largest bioAffinity Technologies buyer in Q4 2023 was Geode Capital Management, an estimated $52.6K added.
  • The largest bioAffinity Technologies seller in Q4 2023 was CAPTRUST Financial Advisors, an estimated $5.13K sold.

Based on aggregated 13F filings for Q4 2023.